1Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH
2Health Services Management and Policy, College of Public Health, The Ohio State University, Columbus, OH
3Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA
4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
5Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA
6HealthPartners Institute, Minneapolis, MN
7Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
8Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA.
Address correspondence to: Macarius M. Donneyong, PhD, MPH, Ohio State University, 495 W. 12th Ave, Columbus, OH 43210. E-mail: donneyong.1@osu.edu
Received 18 November, 2019
Revised 2 January, 2020
Accepted 2 January, 2020
Funding/support: This study was partially funded by the National Institutes of Health, US Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C.
Financial disclosure/conflicts of interest: R.T.C. has received funding from Pfizer. J.A.R. has received funding from Bayer. The other authors have no relevant disclosures.
Supplemental digital content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's Website (www.menopause.org).
